Additional information
| Water Retention | None |
|---|---|
| Hepatotoxicity | Low |
| Lab Test | Not specific |
| Strength | 200 mg |
| Also known as | EIDD-2801 |
| Blood pressure | No significant effects |
| Trade name | Lagevrio |
| Storage conditions | Store at room temperature away from moisture and heat |
| Chemical name | ОІ-D-N4-hydroxycytidine |
| Formula | C13H19N3O7 |
| Substance class | Antiviral medication |
| Main action | Induces viral mutagenesis |
| Half-life | Approximately 7 hours |
| Dosage (medical) | 800 mg twice daily for 5 days |
| Dosage (sports) | Not applicable |
| Effects | Reduces the risk of hospitalization or death in COVID-19 patients |
| Side effects | Diarrhea, nausea, dizziness |
| Use in sports | None |
| Manufacturer | Healing Pharma |
Tavanic 500 mg Sanofi
T3 KASSEL
HCG 5000 I.U. (CHORIOMON) IBSA
Champix Starter Pack Pfizer
Balkan Pharma Parabolan 100mg 10 Ampullen
Spiriva HandiHaler 18mg Boehringer Ingelheim
Fostimon (Merional) 150 IU HMG IBSA
CLENBULL BULL PHARMA
Rovamycine 3.000.000 iu Eczacibasi 

Reviews
There are no reviews yet.